These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25208770)

  • 1. Reimbursement of orphan drugs in Belgium: what (else) matters?
    Picavet E; Cassiman D; Simoens S
    Orphanet J Rare Dis; 2014 Sep; 9():139. PubMed ID: 25208770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.
    Paulden M; Stafinski T; Menon D; McCabe C
    Pharmacoeconomics; 2015 Mar; 33(3):255-69. PubMed ID: 25412735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to orphan drugs despite poor quality of clinical evidence.
    Dupont AG; Van Wilder PB
    Br J Clin Pharmacol; 2011 Apr; 71(4):488-96. PubMed ID: 21395641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European pharmaceutical pricing and reimbursement conference.
    Ehreth J; Williams D
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):37-9. PubMed ID: 19371177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
    Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
    Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
    Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
    Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
    Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medication: 15 years 'EU-directive orphan drugs'].
    Dooms M
    Bull Cercle Benelux Hist Pharm; 2015 Mar; (128):21-6. PubMed ID: 26137669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shining a light in the black box of orphan drug pricing.
    Picavet E; Morel T; Cassiman D; Simoens S
    Orphanet J Rare Dis; 2014 Apr; 9():62. PubMed ID: 24767472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
    Iskrov GG; Raycheva RD; Stefanov RS
    Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysing criteria for price and reimbursement of orphan drugs in Spain.
    Badia X; Gil A; Poveda-Andrés JL; Shepherd J; Tort M
    Farm Hosp; 2019 Jul; 43(4):121-127. PubMed ID: 31276443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study.
    Abdallah K; Claes K; Huys I; Follon L; Calis C; Simoens S
    Orphanet J Rare Dis; 2022 Dec; 17(1):429. PubMed ID: 36494733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.